231 related articles for article (PubMed ID: 204317)
1. Acute effects of cholestyramine on serum lipoprotein concentrations in type II hyperlipoproteinaemia.
Olsson AG; Dairou F
Atherosclerosis; 1978 Jan; 29(1):53-61. PubMed ID: 204317
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein composition and lipoprotein interrelations in 50-year-old men with hyperlipoproteinaemia.
Vessby B; Hedstrand H; Olsson U
Ups J Med Sci; 1976; 81(2):71-8. PubMed ID: 183321
[TBL] [Abstract][Full Text] [Related]
3. Conversion of type III hyperlipoproteinaemia to type IV hyperlipoproteinaemia by a fat-free, carbohydrate rich diet.
Vessby B; Carlson LA
Eur J Clin Invest; 1975 Jul; 5(4):359-64. PubMed ID: 170119
[TBL] [Abstract][Full Text] [Related]
4. The effect of cholestyramine on lipoprotein lipids in patients with primary type IIA hyperlipoproteinemia.
Weisweiler P; Neureuther G; Schwandt P
Atherosclerosis; 1979 Jul; 33(3):295-300. PubMed ID: 226105
[TBL] [Abstract][Full Text] [Related]
5. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
Gavish D; Oschry Y; Fainaru M; Eisenberg S
Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
[TBL] [Abstract][Full Text] [Related]
6. Distribution of lipoproteins triglyceride and lipoprotein cholesterol in an adult population by age, sex, and hormone use- The Pacific Northwest Bell Telephone Company health survey.
Wahl PW; Warnick GR; Albers JJ; Hoover JJ; Walden CE; Bergelin RO; Ogilvie JT; Hazzard WR; Knopp RH
Atherosclerosis; 1981 Apr; 39(1):111-24. PubMed ID: 6941788
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia.
Series JJ; Caslake MJ; Kilday C; Cruickshank A; Demant T; Lorimer AR; Packard CJ; Shepherd J
Metabolism; 1989 Feb; 38(2):153-8. PubMed ID: 2643751
[TBL] [Abstract][Full Text] [Related]
8. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia.
Vessby B; Kostner G; Lithell H; Thomis J
Atherosclerosis; 1982 Jul; 44(1):61-71. PubMed ID: 6214264
[TBL] [Abstract][Full Text] [Related]
9. Cholestyramine in type IIa hyperlipoproteinemia. Is low-dose treatment feasible?
Angelin B; Einarsson K
Atherosclerosis; 1981; 38(1-2):33-8. PubMed ID: 7470203
[TBL] [Abstract][Full Text] [Related]
10. Serum lipoprotein composition in different types of hyperlipoproteinemia.
Carlson LA
Adv Exp Med Biol; 1975; 63():185-99. PubMed ID: 173148
[TBL] [Abstract][Full Text] [Related]
11. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E
Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686
[TBL] [Abstract][Full Text] [Related]
12. Effect of dietary treatment on the lipid, lipoprotein and fatty acid compositions in type IV familial hypertriglyceridemia.
Agheli N; Cloarec M; Jacotot B
Ann Nutr Metab; 1991; 35(5):261-73. PubMed ID: 1776822
[TBL] [Abstract][Full Text] [Related]
13. Plasma lipoprotein metabolism in relation to ischaemic heart disease.
Rogers MP
Biochem Soc Trans; 1982 Jun; 10(3):159-61. PubMed ID: 7106365
[No Abstract] [Full Text] [Related]
14. Pseudohomozygous type II hyperlipoproteinemia.
Morganroth J; Levy RI; McMahon AE; Gotto AM
J Pediatr; 1974 Nov; 85(5):639-43. PubMed ID: 4370845
[No Abstract] [Full Text] [Related]
15. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
[TBL] [Abstract][Full Text] [Related]
16. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
Winocour PH; Durrington PN; Bhatagnar D; Ishola M; Mackness M; Arrol S; Anderson DC
Atherosclerosis; 1992 Mar; 93(1-2):83-94. PubMed ID: 1596307
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase.
Pacy PJ; Mitropoulos KA; Venkatesan S; Watts GF; Reeves BE; Halliday D
Atherosclerosis; 1993 Nov; 103(2):231-43. PubMed ID: 8292098
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K
Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843
[TBL] [Abstract][Full Text] [Related]
19. Serum lipid and lipoprotein concentrations in chronic uremia.
Norbeck HE; Orö L; Carlson LA
Acta Med Scand; 1976; 200(6):487-92. PubMed ID: 189577
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
